New advancements in medicine are fast occurring. However, as this new millennium is bringing hope too many some medical entities appear to be bypassing crucial investigation doctrines, such as, quality innovations, FDA regulations, ethics and treatment benefits. The articles selected provide further insight on current research applications and ethical dilemmas regarding experimental trails. As previously discussed in chapters one and five there are certain ingredients required for a successful investigation but our priority is the benefit of human health.
The article by Rabin reviews robotic surgery devices as a fast expanding field with a growth of 400 percent during the 2007 to 2011 period. This increasing trend of new robotic technologies has forced doctors and nurses to adapt to the new machinery, even though the medical staff are not completely trained to fully work with such technology. For instance, the da Vinci system is robotic surgical device used in a variety of procedures, which has been in retail for the past ten years. Growing concerns of the da Vinci system are rising as reports of malpractice and death are accumulating due to unreported incidents to the FDA. Moreover, an anonymous surveyed revealed that about 56.8 percent of surgeons admitted to “experience irrecoverable operative malfunctions” with the device (Rabin 2013). Another worry is the lack of evidence supporting long-term advantages as well as the unknown negative affects of using the da Vinci system.
Another piece written by Beil reveals the unsteady fast-paced growing field of stem cell research in nonscientific settings under the umbrella of regenerative medicine. This eye-opening story reveals the wide international market of companies promoting “regeneration” with stem cells in a range of diseases and thus evading the scientific facts of the inconclusive studies. Scientists continue to search for the proper conditions and implantation areas for stem cells to regenerate at any location (Beil 2013) therefore safety measures remain a concern. One stem cell company stated that their main priority was releasing products into the market not publishing data for research purposes.